Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ Founder
Transaction Solidifies Company’s Near-Term Strategic Focus on Advancing Clinical Development of NX-13 Company Remains On-Track…
Transaction Solidifies Company’s Near-Term Strategic Focus on Advancing Clinical Development of NX-13 Company Remains On-Track…
Transaction Solidifies Company’s Near-Term Strategic Focus on Advancing Clinical Development of NX-13 Company Remains On-Track…
THE WOODLANDS, Texas, Feb. 28, 2023 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will…
THE WOODLANDS, Texas, Feb. 28, 2023 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will…
Conference Call and Webcast to be held March 7, 2023 at 8:00 a.m. Eastern Time…
Conference Call and Webcast to be held March 7, 2023 at 8:00 a.m. Eastern Time…
NEWS RELEASEFEBRUARY 28, 2023, 4:30 pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM –…
NEWS RELEASEFEBRUARY 28, 2023, 4:30 pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM –…
EDMONTON, ALBERTA, CHATHAM, ONTARIO and TEL-AVIV, ISRAEL, Feb. 28, 2023 (GLOBE NEWSWIRE) — Atlas Global…
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology…
EDMONTON, ALBERTA, CHATHAM, ONTARIO and TEL-AVIV, ISRAEL, Feb. 28, 2023 (GLOBE NEWSWIRE) — Atlas Global…
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology…
Cash, cash equivalents and current financial instruments totaled €140.2 million as of December 31, 2022….
Cash, cash equivalents and current financial instruments totaled €140.2 million as of December 31, 2022….
HOLLISTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce…
HOLLISTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce…
Paltusotine’s Phase 3 PATHFNDR-1 study enrollment complete and topline data expected in 3Q 2023 Paltusotine’s…
Paltusotine’s Phase 3 PATHFNDR-1 study enrollment complete and topline data expected in 3Q 2023 Paltusotine’s…
SAN FRANCISCO, Feb. 28, 2023 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced…
Full Year 2022 total revenues of $667.2 million, a 15% increase compared to full year…